Galecto (GLTO)
Preclinical biotech targeting mutant calreticulin blood disorders.
Something off on this page? Send us feedback.
Damora Therapeutics, formerly Galecto, is a preclinical biotechnology company developing therapies for hematologic disorders. Its main work centers on mutCALR-targeted biologics for essential thrombocythemia and myelofibrosis, led by DMR-001.
Damora Therapeutics, formerly Galecto, is a Nasdaq-listed biotechnology company focused on treatments for blood disorders. After acquiring privately held Damora in late 2025 and changing its name in March 2026, the company shifted its center of gravity to mutant calreticulin-driven myeloproliferative neoplasms, including essential thrombocythemia and myelofibrosis.
Its lead program, DMR-001, is an investigational monoclonal antibody designed to target mutCALR and is being prepared for regulatory submission in mid-2026. Damora also lists DMR-002 and DMR-003 as additional mutCALR programs, while its older GB3226 acute myeloid leukemia program has been deprioritized. The company remains preclinical, so progress depends on regulatory clearance, human safety and efficacy data, manufacturing execution, and access to capital for later-stage development.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $540.5M · Total debt $0 · Total assets $543.6M · Shareholders' equity $516.1M
- Revenue
- $0
- Operating income
- −$35.0M
- Net income
- −$31.2M
No dividends on record.
| Institutions64 holders · as of Mar 31, 2026 | 90.71% | 56.00M shares | |
| Insiders6 holders · as of Feb 12, 2026 | 0.97% | 599.5K shares | |
| Otherremainder | 8.32% | 5.14M shares |
61.74M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (61.74M in the company's Sep 3, 2026 report, 1.60M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
FMR LLCInstitution | 14.65% | 9.05M | 13Fas of Mar 31, 2026 |
Fairmount Funds Management LLCInstitution | 14.11% | 8.71M | 13Fas of Mar 31, 2026 |
Avoro Capital Advisors LLCInstitution | 6.13% | 3.78M | 13Fas of Mar 31, 2026 |
VR Adviser, LLCInstitution | 5.84% | 3.60M | 13Fas of Mar 31, 2026 |
FCPM Iii Services B.V.Institution | 3.95% | 2.44M | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 2, 2026 | Lori Firmani | officer: Chief Financial Officer | −135 | $21.41 |
| Jan 2, 2026 | Garrett Winslow | officer: General Counsel | −255 | $21.38 |
| Jan 2, 2026 | Hans T. Schambye | director, officer: Chief Executive Officer | −700 | $21.38 |
Not reported.